Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Videos|December 6, 2016
The Challenges of Limited Distribution Networks
Author(s)Laurie Toich, Assistant Editor
Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP, senior director of Specialty Clinical Services at Managed Health Care Associates, discusses how specialty pharmacies can navigate limited distribution networks.
Advertisement
Stacey Ness, PharmD, RPh, CSP, MSCS, AAHIVP, senior director of Specialty Clinical Services at Managed Health Care Associates, discusses, how specialty pharmacies can navigate limited distribution networks.
Advertisement
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
2
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5